© 2024 HSP News Service, L.L.C.
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...
On October 11, 2023, the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) was approved for patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA...
Lung cancer incidence overall has been declining in the United States since 1992—and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively—and overall mortality rates have declined in both men and women because of smoking cessation efforts and advances in therapy and early...
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP...
As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. Background Australia...
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...
The immune checkpoint inhibitor durvalumab may be safe and effective at improving overall survival in patients who have advanced or metastatic non–small cell lung cancer (NSCLC) and borderline performance status, according to a recent study published by Shaverdashvili et al in eClinicalMedicine....
Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to Dr. ...
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, was invited to discuss the subgroup analysis of small cell lung cancer (SCLC) in the DS7300-A-J101 trial. She first noted that the antibody-drug conjugate...
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 A...
Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Findings from the Taiwan National Lung Cancer Early Detection Program have shown that lung cancer screening by low-dose computed tomography (CT) can detect tumors at an early-enough phase to allow for effective intervention. In a recent analysis, 85% of tumors detected by screening were stage 0 or...
The results of a recent study from the United Kingdom could spell the end of a long-standing treatment strategy for mesothelioma, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer.1 When combined with...
The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...
Low-dose radiotherapy in combination with the monoclonal antibody durvalumab and chemotherapy as neoadjuvant therapy was well tolerated in patients with potentially resectable stage III non–small cell lung cancer (NSCLC), according to a small study conducted in China and presented at the...
Discussant of the abstract on the ASTRUM-004 trial, Justin F. Gainor, MD, emphasized the significant, positive improvements in survival among patients randomly assigned to receive the PD-1 inhibitor serplulimab vs placebo. Dr. Gainor is Director of the Center for Thoracic Cancers Program, Director ...
A novel treatment approach to squamous non–small cell lung cancer (NSCLC) may improve the prognosis for patients with previously limited treatment options, according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 Findings from ...
Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated resectable stage II–IIIB NSCLC; the ALINA study of alectinib vs chemotherapy in patients with early-stage ALK-positive NSCLC; and overall survival data from KEYNOTE-671, which established the role of chemoimmunotherapy and pembrolizumab. Dr. Naidoo also reviews data in small cell lung and thymic cancers.
As reported in The Lancet by Chu et al, a phase III trial conducted in Canada, Italy, and France showed that the addition of pembrolizumab to chemotherapy improved survival in previously untreated patients with advanced pleural mesothelioma. Study Details In the multicenter open-label trial, 440...
The addition of durvalumab to neoadjuvant chemotherapy led to higher rates of R0 resections and posed no apparent impediments to successful surgery for resectable non–small cell lung cancer (NSCLC), according to findings from the randomized phase III AEGEAN trial presented at the International...
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses new findings on AZD7789, which targets PD-1 and TIM-3, in patients with stage IIIB–IV non–small cell lung cancer (NSCLC) with previous anti–PD-L1 therapy. This bispecific antibody showed manageable safety and preliminary efficacy at tolerable doses (Abstract 1313MO).
On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (Abstract OA05.03). The phase III HERTHENA-Lung02 trial is ongoing.
As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic...
Genetic information collected from healthy tissue near lung tumors may be predictive of posttreatment cancer recurrence compared with analysis of the tumors themselves, according to a novel study published by Dolgalev et al in Nature Communications. Background Lung adenocarcinomas are tumors that...
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) (Abstract 1261O).
An interim analysis of the phase III LIBRETTO-431 trial has shown significantly improved progression-free survival with first-line selpercatinib vs platinum-based chemotherapy with or without pembrolizumab in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The...